Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistant estrogen receptor-positive breast cancer.
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic breast cancer: Part I results.”
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer."
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
